AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$WAT

Stifel raises Waters stock price target to $470 on strong quarter

Stifel raised its price target for Waters Corp. (NYSE:WAT) to $470 from $420, citing strong Q3 performance and mid-single-digit growth outlook for 2027. The stock trades near its 52-week high at $459.90. Waters reported Q3 2026 earnings of $4.10 per share, beating estimates, and raised its full-year outlook.

Original reporting
investing.com
Published Nov 4, 2026, 8:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$WAT
Bullish
high confidence
Mentioned
$WAT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The price‑target hike signals confidence in continued organic growth and may drive short‑term buying.

02

Market read

Waters' earnings beat and higher target could lift the stock and related sector.

03

What to watch

Potential supply chain constraints in China could temper growth.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Stifel’s upgrade follows Waters' Q3 2026 earnings beat and raised full‑year outlook.

Company-level read

Ticker impact

$WATBullishHigh confidence
Context

Stifel raised its price target on Waters Corp. to $470, citing strong Q3 earnings and growth outlook.

Expected impact

likely upward pressure as investors price in higher target

Evidence & confidence

Target increase from $420 to $470 reflects confidence in earnings beat and growth drivers, prompting buying interest.

Market effects

Sector

Positive outlook for analytical instruments may lift peers in the life‑science sector.

Regional

Strong China demand noted could benefit other US exporters to Asia.

Global

Reinforces broader optimism in biotech and analytical equipment markets.

Counterpoint

What could challenge this read

Target may be overly optimistic given high valuation multiples.

Key entities

  • Company
    Waters Corp.

    Provider of analytical instruments and consumables.

  • Research Firm
    Stifel

    Equity research analyst raising target.

Read at source← All news

StoryWaters Corp. posts Q3 2026 revenue of $1.767 B, raises full‑year guidance and announces MOBILion acquisition

Also covered by

4 outlets

Related articles

NOV 4
$WATHighAI 8/10

Bernstein raises Waters stock price target to $535 on earnings beat

Bernstein raised its price target on Waters Corp. (WAT) to $535 from $450, citing strong Q3 2026 results. Revenue grew 10% in constant currency, and adjusted EPS of $4.10 beat estimates. The company raised full-year 2026 guidance for revenue and EPS. Bernstein described the 2027 outlook as conservative, with mid-single-digit-plus organic growth expected. Other analysts also raised price targets following the earnings beat.

investing.com2 min
NOV 4
$WATMed

KeyBanc raises Waters stock price target to $500 on guidance boost

KeyBanc raised its price target for Waters Corp. (WAT) to $500 from $460, citing strong Q3 results and raised guidance. WAT reported 10% revenue growth and 30.1% adjusted operating margin, exceeding estimates. The stock is up 52% in six months, trading near $460. Stifel also raised its target to $470 but maintained a Hold rating. WAT's full-year guidance was increased to 9.1%-9.7% growth, with AI and China growth cited as positive factors.

investing.com2 min
NOV 4
$WATMedAI 8/10

Waters Q3 Earnings Call Highlights

Waters Corporation (WAT) reported Q3 revenue of $575M in Advanced Diagnostics, up 2%, and $500M in Diagnostic Solutions, flat. Microbiology revenue grew 4% outside China but declined 20% in China. Clinical Business Unit revenue rose 17%, and Materials Sciences revenue increased 7%. The company expects to recover revenue from reagent-rental compliance and announced partnerships for its Onclarity HPV kit.

finance.yahoo.com2 min